Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in the Japanese population

被引：1

作者：

Nakagawa, Kazuhiko ^{[1
]}

Matsumura, Koichi ^{[2
]}

Scory, Tayler ^{[3
]}

Farris, Megan S. ^{[3
]}

Larkin-Kaiser, Kelly A. ^{[3
]}

Kikkawa, Hironori ^{[2
]}

Ivanova, Jasmina I. ^{[4
]}

Wilner, Keith D. ^{[5
]}

机构：

[1] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan

[2] Pfizer Japan, Tokyo, Japan

[3] Medlior Hlth Outcomes Res Ltd, Calgary, AB T2C 5P9, Canada

[4] Pfizer, New York, NY 10017 USA

[5] Pfizer, La Jolla, CA 92121 USA

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 01期

关键词：

EGFRpositive; Japanese population; network meta-analysis; non-small-cell lung cancer; progression-free survival; tyrosine kinase inhibitors; RANDOMIZED PHASE-III; OPEN-LABEL; EGFR MUTATIONS; CARBOPLATIN-PACLITAXEL; COMPARING GEFITINIB; TARGETED THERAPIES; TYROSINE KINASE; ASIA-PACIFIC; ERLOTINIB; ADENOCARCINOMA;

D O I：

10.2217/fon-2020-0651

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background:FiveEGFR-tyrosine kinase inhibitors (EGFRTKIs) are currently available in the first-line setting for non-small-cell lung cancer (NSCLC) in Japan. The aim here was to compare the relative efficacy ofEGFRTKIs in the Japanese population.Materials & methods:A systematic review identified randomized controlled trials examining the efficacy of first-lineEGFRTKIs. A Bayesian network meta-analysis was used to assess theseEGFRTKI comparisons for progression-free survival (PFS).Results:A total of seven randomized controlled trials were identified and considered for network meta-analysis. Dacomitinib showed a trend toward improved PFS versus all comparators.Conclusion:Dacomitinib demonstrated a trend toward improved PFS and therefore, should be considered one of the standard first-line therapies for Japanese patients diagnosed with EGFR+ non-small-cell lung cancer.

引用

页码：103 / 115

页数：13

共 66 条

[1] The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV [J].

Akamatsu, Hiroaki ;

Ninomiya, Kiichiro ;

Kenmotsu, Hirotsugu ;

Morise, Masahiro ;

Daga, Haruko ;

Goto, Yasushi ;

Kozuki, Toshiyuki ;

Miura, Satoru ;

Sasaki, Takaaki ;

Tamiya, Akihiro ;

Teraoka, Shunsuke ;

Tsubata, Yukari ;

Yoshioka, Hiroshige ;

Hattori, Yoshihiro ;

Imamura, Chiyo K. ;

Katsuya, Yuki ;

Matsui, Reiko ;

Minegishi, Yuji ;

Mizugaki, Hidenori ;

Nosaki, Kaname ;

Okuma, Yusuke ;

Sakamoto, Setsuko ;

Sone, Takashi ;

Tanaka, Kentaro ;

Umemura, Shigeki ;

Yamanaka, Takeharu ;

Amano, Shinsuke ;

Hasegawa, Kazuo ;

Morita, Satoshi ;

Nakajima, Kazuko ;

Maemondo, Makoto ;

Seto, Takashi ;

Yamamoto, Nobuyuki .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (07) :731-770

[2] Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis [J].

Batson, Sarah ;

Mitchell, Stephen A. ;

Windisch, Ricarda ;

Damonte, Elisabetta ;

Munk, Veronica C. ;

Reguart, Noemi .

ONCOTARGETS AND THERAPY, 2017, 10 :2473-2482

[3]

Bormann I, DIGITIZEIT SOFTWARE

[4] General methods for monitoring convergence of iterative simulations [J].

Brooks, SP ;

Gelman, A .

JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS, 1998, 7 (04) :434-455

[5] Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective [J].

Cabanero, M. ;

Sangha, R. ;

Sheffield, B. S. ;

Sukhai, M. ;

Pakkal, M. ;

Kamel-Reid, S. ;

Karsan, A. ;

Ionescu, D. ;

Juergens, R. A. ;

Butts, C. ;

Tsao, M. S. .

CURRENT ONCOLOGY, 2017, 24 (02) :111-119

[6]

Centre for Reviews and Dissemination (CRD), 2009, CRDS GUIDANCE UNDERT

[7] Graphical Tools for Network Meta-Analysis in STATA [J].

Chaimani, Anna ;

Higgins, Julian P. T. ;

Mavridis, Dimitris ;

Spyridonos, Panagiota ;

Salanti, Georgia .

PLOS ONE, 2013, 8 (10)

[8]

Dias S, 2011, NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials

[9] Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer [J].

Franek, Jacob ;

Cappelleri, Joseph C. ;

Larkin-Kaiser, Kelly A. ;

Wilner, Keith D. ;

Sandin, Rickard .

FUTURE ONCOLOGY, 2019, 15 (24) :2857-2871

[10] Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026. [J].

Furuya, Naoki ;

Fukuhara, Tatsuro ;

Saito, Haruhiro ;

Watanabe, Kana ;

Sugawara, Shunichi ;

Iwasawa, Shunichiro ;

Tsunezuka, Yoshio ;

Yamaguchi, Ou ;

Okada, Morihito ;

Yoshimori, Kouzou ;

Nakachi, Ichiro ;

Gemma, Akihiko ;

Azuma, Koichi ;

Hagiwara, Koichi ;

Nukiwa, Toshihiro ;

Morita, Satoshi ;

Kobayashi, Kunihiko ;

Maemondo, Makoto .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 6 7 →